With a U.S. biotech identified as One Bio, Jiangsu Hengrui Pharmaceutical Co. Ltd. has inked an out-licensing deal potentially worth $1.05 billion for its asthma and chronic sinusitis-targeting drug, SHR-1905. The latest deal gives One Bio exclusive rights to develop, produce and commercialize SHR-1905 worldwide, excluding the greater China territory.
A team from Siemens Medical Solutions Inc. presented a new artificial intelligence (AI) model that can predict people’s risk of multiple sclerosis (MS), at the 2023 American Association for Clinical Chemistry (AACC) annual scientific meeting in Anaheim, Calif.
Peptidream Inc. and Modulus Discovery Inc. have nominated the first clinical development candidate arising from the companies’ strategic drug discovery partnership.
Swiss researchers have gained new insights into the relationship between aging, inflammation, neurodegeneration and cognitive decline. EPFL professor Andrea Ablasser and her team showed that brain aging was driven by microglial activation of the cGAS/STING pathway.
The notion of taking aim at the galectin pathway across varied therapeutic areas has gained major traction in recent years, with a handful of companies drawing Wall Street’s interest as efforts plow forth in conditions as varied as cancer, liver fibrosis and Alzheimer’s disease.
Haisco Pharmaceutical Group Co. Ltd. has described propionic acid derivatives acting as integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of inflammatory disorders.
Researchers from OSE Immunotherapeutics SA have published preclinical data for the novel anti-ChemR23 monoclonal antibody (MAb) (OSE-230) with anti-inflammatory properties, being evaluated for the potential treatment of cancer.
Recludix Pharma Inc. has entered into a strategic collaboration with Sanofi SA to develop and commercialize first-in-class oral small-molecule STAT6 (signal transducer and activator of transcription 6) inhibitors for patients with immunological and inflammatory diseases. STAT6 is believed to play a key role in multiple dermatological and respiratory diseases.
Dismissed as undruggable in the early 2000s, Src homology 2 domains are now viable and at the heart of Recludix Pharma Inc.’s new deal with Sanofi SA’s U.S. unit. The two will collaborate on developing and commercializing treatments for immunological and inflammatory diseases. In the near term, Recludix will get $125 million, but long term it could add up to $1.2 billion in milestones. Recludix could also bring in up to double-digit royalties on possible future product sales.